Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This randomized controlled clinical trial tested whether four weeks of daily kombucha changes the gut microbiome and health markers in healthy adults eating a Western diet. It combined microbiome, biochemical, and immune profiling. Stool underwent shotgun metagenomic sequencing, classified into Operational Genomic Units. Blood was tested for metabolic parameters and inflammation markers IL-6, IL-10, and CRP. The primary outcome was change in microbiome composition; secondary outcomes were metabolic and immune markers, compared over three time points.
Who was studied?
The cohort was healthy free-living adults in San Diego County, USA, aged 21 to 55 with BMI between 18 and 29.9. Thirty enrolled, and 24 completed analysis: 16 in the kombucha group and 8 controls, comprising 11 men and 13 women. After four weeks on a low-fiber, low-polyphenol Western diet, the kombucha group drank one 16 oz bottle daily, split into two servings, for four weeks while controls continued the diet alone. Participants provided stool and blood at baseline, week four, and week eight.
What were the most important findings?
There were no significant changes in biochemical parameters or circulating inflammation markers across the full cohort. Overall microbial diversity did not differ between groups, though Shannon diversity fell modestly within the kombucha group from baseline to end (q = 0.016). Community composition shifted significantly with kombucha (Bray Curtis PERMANOVA p = 0.025), enriching a kombucha-borne probiotic and other short-chain-fatty-acid producers. Paired analysis showed increased fasting insulin and HOMA-IR within the kombucha group (both p = 0.021), while controls showed reduced HDL cholesterol (p = 0.042).
What are the greatest implications of this study?
The findings suggest that short-term kombucha modestly reshapes the gut microbiome in healthy people, mainly by introducing the beverage's own probiotic, without broad metabolic or anti-inflammatory benefits. The authors caution against overstating health effects. The small sample, short duration, and large person-to-person variability likely limited detectable change on a Western-diet background. As the first study linking kombucha consumption to the human gut microbiome, it provides a baseline for larger, longer trials combining immune, metabolic, and microbiome data to test therapeutic potential.